Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07823829) titled 'A Phase I/II Trial of CT1190B in Patients With Relapsed/Refractory Large B-Cell Lymphoma' on Sept. 8.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: UCARsgen Biotech Limited
Condition:
Large B-Cell Lymphoma (LBCL)
Intervention:
Drug: CT1190B intravenous infusion
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: October 15, 2026
Target Sample Size: 68
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT078...